Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Updates in Mantle Cell Lymphoma

Access Activity

Overview / Abstract:

Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now.


Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin lymphoma that comprises approximately 5% of all lymphomas.Compared with patients who have other aggressive lymphomas, patients with MCL often do not respond as well to treatment (ACS, 2019).Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 4 and 5 years (LLS, 2021). Though there are several effective options, there is no currently accepted standard of care for frontline treatment of MCL (Hanel & Epperla, 2020). Selecting treatments for relapsed/refractory disease is complicated by multiple factors individual to the patient (Cortelazzo et al 2020). In order to select optimal treatments for MCL, it is vital that clinicians be familiar with the latest research. In this activity, John P. Leonard, MD, will discuss the latest research into prognostic markers of MCL, the efficacy and safety of novel therapeutic strategies, and approaches to optimize tolerability of treatments.


Hematologist/oncologists, hematology/oncology fellows, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies.


Upon completion of this activity, participants should be able to
Discuss predictive and prognostic markers that can individualize treatment selection for patients with MCL
Assess emerging efficacy and safety data on novel therapeutic strategies for MCL
Evaluate strategies to optimize the safety and tolerability of novel therapies for MCL


Feb 14, 2023


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physical Therapy CE, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.0 CME | 1.0 NPCD | 1.0 CPE | MOC | ILNA



Presenters / Authors / Faculty

John Leonard, MD
Richard T. Silver Distinguised Professor of Hematology and Oncology
Weill Cornell Medicine

Activity Specialities / Related Topics

Hematology, Oncology / Cancer / Radiation Therapy, Pharmacology

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from BeiGene, Bristol Myers Squibb, Merck, and Seagen.

Keywords / Search Terms

i3 Health i3 health, lung cancer, mantle cell lymphoma, lymphoma, MCL, hematology, CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD, CME ,Free CE CME, Free CE CME, ANCC Free CE CME Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map